PTC Therapeutics, Inc. (PTCT) Key Metrics
PTCT valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $4.94B
- Enterprise value
- $3.67B
- P/E (TTM)
- —
- Forward P/E
- 22.7
- PEG ratio
- 0.81
- Price / sales
- 4.9 10-yr median 4.4
- Price / book
- — 10-yr median 4.6
- EV / EBITDA
- 21.2
- Dividend yield
- —
- Beta
- 0.49
PTCT key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPTCT valuation Price multiples at each fiscal year-end price.
Price / sales−9.8%
3.9
2025 · hover or tap a bar for each year
20162025
Free cash flow yield+11.4 pts
6.1%
2025 · hover or tap a bar for each year
20162025
PTCT returns How much profit the business earns on the capital it uses.
Return on invested capital+274.9 pts
212.6%
2025 · hover or tap a bar for each year
20162025
Return on assets+49.8 pts
29.7%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin+46.3 pts
23.8%
2025 · hover or tap a bar for each year
20162025
Asset turnover+67.8%
0.75
2025 · hover or tap a bar for each year
20162025
PTCT per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+86.7%
$19.60
2025 · hover or tap a bar for each year
20162025
Earnings per share
$7.73
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
$4.66
2025 · hover or tap a bar for each year
20162025
Book value per share
−$2.32
2025 · hover or tap a bar for each year
20162025
Shares outstanding+14.9%
88.3M
2025 · hover or tap a bar for each year
20162025
PTCT financial health Debt, liquidity and how easily interest is covered.
Net debt−$569.7M
$761.7M
2025 · hover or tap a bar for each year
20162025
Current ratio−0.1%
2.35
2025 · hover or tap a bar for each year
20162025
Interest coverage
5.6
2025 · hover or tap a bar for each year
20162025
Debt / assets−35.6%
0.93
2025 · hover or tap a bar for each year
20162025
PTCT efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−36 days
36 days
2025 · hover or tap a bar for each year
20162025
Days of inventory+91 days
262 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding+85 days
160 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle−31 days
138 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue+8.1 pts
17.3%
2025 · hover or tap a bar for each year
20162025
PTCT valuation history
Fiscal year-endToday10-year median
PTCT returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PTCT debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PTCT price vs earnings per share
Share price at year-endEPS (right axis)
PTCT key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $6.71B | $3.47B | $2.06B | $2.74B | $2.81B | $4.03B | $2.83B | $1.60B | $653.6M | $371.4M |
| Enterprise value | $7.47B | $4.80B | $3.41B | $3.79B | $2.48B | $3.35B | $2.47B | $1.52B | $668.5M | $278.9M |
| P/E ratio | 9.8 | — | — | — | — | — | — | — | — | — |
| Price / sales | 3.9 | 4.3 | 2.2 | 3.9 | 5.2 | 10.6 | 9.2 | 6.0 | 3.4 | 4.5 |
| Price / book | — | — | — | — | — | 8.4 | 4.8 | 4.6 | 4.2 | 3.1 |
| Price / free cash flow | 16.3 | — | — | — | — | — | — | — | — | — |
| Price / operating cash flow | 9.4 | — | — | — | — | — | — | — | — | — |
| EV / sales | 4.3 | 5.9 | 3.6 | 5.4 | 4.6 | 8.8 | 8.0 | 5.8 | 3.4 | 3.4 |
| EV / EBITDA | 8.4 | — | — | — | — | — | — | — | — | — |
| EV / free cash flow | 18.2 | — | — | — | — | — | — | — | — | — |
| Earnings yield | 10.2% | −10.5% | −30.4% | −20.4% | −18.7% | −10.9% | −8.9% | −8.0% | −12.1% | −38.3% |
| Free cash flow yield | 6.1% | −5.2% | −13.5% | −18.6% | −12.0% | −6.2% | −5.1% | −2.7% | −2.0% | −28.4% |
| Dividend yield | — | — | — | — | — | — | — | — | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Share price at fiscal year-end | $75.96 | $45.14 | $27.56 | $38.17 | $39.83 | $61.03 | $48.03 | $34.32 | $16.68 | $10.91 |
| Per share | ||||||||||
| Revenue per share | $19.60 | $10.50 | $12.53 | $9.74 | $7.64 | $5.77 | $5.22 | $5.68 | $4.96 | $2.43 |
| Earnings per share | $7.73 | −$4.73 | −$8.37 | −$7.79 | −$7.43 | −$6.64 | −$4.27 | −$2.75 | −$2.02 | −$4.17 |
| Operating cash flow per share | $8.05 | −$1.40 | −$2.12 | −$4.97 | −$3.57 | −$2.94 | −$1.68 | −$0.59 | −$0.26 | −$3.04 |
| Free cash flow per share | $4.66 | −$2.37 | −$3.73 | −$7.10 | −$4.78 | −$3.79 | −$2.45 | −$0.93 | −$0.34 | −$3.09 |
| Cash per share | $22.03 | $14.83 | $11.72 | $5.73 | $10.98 | $16.71 | $11.66 | $4.89 | $4.88 | $6.80 |
| Book value per share | −$2.32 | −$14.29 | −$10.94 | −$4.84 | $0.02 | $7.30 | $10.10 | $7.53 | $3.99 | $3.51 |
| Tangible book value per share | −$7.66 | −$16.91 | −$17.11 | −$15.83 | −$11.43 | −$4.78 | −$3.37 | −$9.29 | −$2.80 | $3.51 |
| Dividends per share | — | — | — | — | — | — | — | — | $0.00 | $0.00 |
| Capex per share | $3.40 | $0.97 | $1.61 | $2.13 | $1.21 | $0.85 | $0.77 | $0.33 | $0.08 | $0.05 |
| Debt per share | $30.65 | $32.16 | $29.79 | $20.38 | $6.27 | $6.37 | $5.57 | $3.29 | $5.26 | $4.09 |
| Shares outstanding | 88.3M | 76.8M | 74.8M | 71.7M | 70.5M | 66.0M | 58.9M | 46.6M | 39.2M | 34.0M |
| Change in shares outstanding | +14.9% | +2.7% | +4.3% | +1.8% | +6.7% | +12.2% | +26.4% | +18.9% | +15.1% | +1.2% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | — | — | −216.7% | −81.4% | −53.2% | −50.5% | −57.2% | −68.0% |
| Return on invested capital (ROIC) | 212.6% | −62.3% | −56.1% | −189.3% | — | — | −74.4% | −40.8% | −51.2% | −120.6% |
| Return on assets (ROA) | 29.7% | −20.2% | −34.8% | −30.7% | −25.3% | −22.9% | −18.3% | −17.0% | −23.9% | −44.6% |
| Return on tangible assets | 28.1% | −24.2% | −43.7% | −60.9% | −46.3% | −31.1% | −30.3% | −38.1% | −62.9% | −52.8% |
| Free cash flow margin | 23.8% | −22.6% | −29.8% | −72.9% | −62.5% | −65.7% | −46.9% | −16.3% | −6.8% | −127.4% |
| Income quality (OCF / net income) | 1.04 | — | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $2.71B | $2.47B | $2.23B | $1.46B | $441.7M | $420.4M | $328.0M | $153.0M | $206.1M | $139.1M |
| Cash & short-term investments | $1.95B | $1.14B | $876.7M | $410.7M | $773.4M | $1.10B | $686.6M | $227.6M | $191.2M | $231.7M |
| Net debt | $761.7M | $1.33B | $1.35B | $1.05B | −$331.7M | −$683.2M | −$358.5M | −$74.6M | $14.9M | −$92.6M |
| Debt / equity | — | — | — | — | 307.17 | 0.87 | 0.55 | 0.44 | 1.32 | 1.16 |
| Debt / assets | 0.93 | 1.45 | 1.18 | 0.86 | 0.23 | 0.19 | 0.20 | 0.14 | 0.53 | 0.52 |
| Net debt / EBITDA | 0.86 | — | — | — | — | — | — | — | — | — |
| Current ratio | 2.35 | 2.35 | 2.02 | 1.71 | 1.52 | 4.44 | 3.30 | 1.92 | 3.04 | 5.27 |
| Quick ratio | 2.27 | 2.31 | 1.97 | 1.65 | 1.49 | 4.37 | 3.22 | 1.83 | 2.90 | 5.23 |
| Interest coverage | 5.6 | -1.8 | -3.4 | -4.9 | -4.4 | -7.7 | -19.3 | -9.2 | -5.3 | -16.0 |
| Working capital | $1.31B | $784.5M | $615.5M | $287.5M | $264.0M | $954.4M | $543.4M | $154.1M | $167.0M | $211.7M |
| Invested capital | $556.4M | $233.3M | $533.8M | $703.7M | −$330.2M | −$201.2M | $235.8M | $276.2M | $171.3M | $27.0M |
| Tangible asset value | −$676.4M | −$1.30B | −$1.28B | −$1.14B | −$805.7M | −$315.7M | −$198.5M | −$432.6M | −$109.5M | $119.6M |
| Net current asset value | −$830.1M | −$1.44B | −$1.50B | −$1.36B | −$1.16B | −$494.6M | −$250.2M | −$447.6M | $13.8M | $111.5M |
| Graham net-net per share | −$11.13 | −$19.95 | −$22.74 | −$21.11 | −$15.22 | −$8.49 | −$4.95 | −$10.35 | −$0.21 | $2.98 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | 17.3% | 9.2% | 12.9% | 21.8% | 15.8% | 14.7% | 14.8% | 5.9% | 1.6% | 2.1% |
| Capex / operating cash flow | 42.2% | — | — | — | — | — | — | — | — | — |
| Capex / depreciation | 7.73 | 0.98 | 0.51 | 1.18 | 1.33 | 1.29 | 1.41 | 0.60 | 0.18 | 0.54 |
| Stock-based compensation / revenue | 4.3% | 9.2% | 14.0% | 15.8% | 19.2% | 18.5% | 13.7% | 12.6% | 15.7% | 42.3% |
| R&D / revenue | 26.3% | 66.2% | 71.1% | 93.2% | 100.4% | 125.4% | 83.9% | 65.0% | 60.4% | 142.2% |
| SG&A / revenue | 20.1% | 37.3% | 37.2% | 42.9% | 53.0% | 64.4% | 66.0% | 58.0% | 62.4% | 117.4% |
| Efficiency | ||||||||||
| Days sales outstanding | 35.9 | 72.2 | 61.6 | 69.5 | 61.1 | 60.1 | 73.4 | 74.7 | 61.3 | 79.5 |
| Days of inventory on hand | 261.6 | 171.0 | 146.0 | 153.8 | 195.1 | 365.9 | 532.4 | 387.1 | 496.6 | 2.6 |
| Days payables outstanding | 159.6 | 74.1 | 92.8 | 205.5 | 235.4 | 279.3 | 245.5 | 306.6 | 860.5 | 28.3 |
| Cash conversion cycle (days) | 137.8 | 169.1 | 114.7 | 17.9 | 20.8 | 146.8 | 360.3 | 155.1 | -302.6 | 53.8 |
| Receivables turnover | 10.18 | 5.05 | 5.93 | 5.25 | 5.97 | 6.07 | 4.97 | 4.89 | 5.95 | 4.59 |
| Payables turnover | 2.29 | 4.92 | 3.93 | 1.78 | 1.55 | 1.31 | 1.49 | 1.19 | 0.42 | 12.90 |
| Inventory turnover | 1.40 | 2.13 | 2.50 | 2.37 | 1.87 | 1.00 | 0.69 | 0.94 | 0.74 | 138.39 |
| Asset turnover | 0.75 | 0.45 | 0.52 | 0.38 | 0.26 | 0.20 | 0.22 | 0.35 | 0.59 | 0.26 |
| Average receivables | $170.1M | $159.7M | $158.2M | $133.0M | $90.2M | $62.7M | $61.7M | $54.2M | $32.7M | $18.0M |
| Average payables | $31.4M | $11.7M | $16.7M | $25.2M | $20.8M | $14.5M | $8.2M | $10.6M | $10.8M | $9.1M |
| Average inventory | $51.4M | $26.9M | $26.2M | $18.8M | $17.3M | $19.0M | $17.7M | $13.4M | $6.2M | $850,000 |
| Intangibles / total assets | 16.3% | 11.8% | 24.4% | 46.2% | 41.6% | 36.1% | 48.8% | 70.0% | 67.9% | 0.0% |
Computed from PTCT's annual financial statements (latest annual report filed February 19, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PTCT valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), PTC Therapeutics traded at 9.8 times earnings. PTC Therapeutics earned a return on invested capital of 212.6% in fiscal 2025. It ended the year with $2.7 billion of debt and $1.9 billion in cash and short-term investments, net debt of $761.7 million. The share count rose 159.4% from 34.0M to 88.3M over 9 years.
See the PTCT income statement, the PTCT chart for price history, or the PTCT stock overview for the latest quote and news.
PTCT key metrics FAQ
What is PTC Therapeutics's P/E ratio?
PTC Therapeutics traded at 9.8 times earnings at the end of fiscal 2025.
What is PTC Therapeutics's EV/EBITDA?
PTC Therapeutics's enterprise value was 8.4 times EBITDA at the end of fiscal 2025 (enterprise value $7.5 billion, EBITDA $887.7 million); the current EV/EBITDA is 21.2.
What is PTC Therapeutics's ROIC?
PTC Therapeutics's return on invested capital was 212.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does PTC Therapeutics have?
PTC Therapeutics had total debt of $2.7 billion at the end of fiscal 2025 and $761.7 million of net debt (0.86 times EBITDA).
What is PTC Therapeutics's free cash flow yield?
PTC Therapeutics generated $411.2 million of free cash flow in fiscal 2025, a free cash flow yield of 6.1% on its market value at year-end ($6.7 billion).
What is PTC Therapeutics's current ratio?
PTC Therapeutics's current ratio was 2.35 at the end of fiscal 2025: current assets were 2.35 times current liabilities.